United Therapeutics director awarded stock options
United Therapeutics Corp director Louis W. Sullivan received an annual non-employee director stock option award covering 2,380 shares of common stock at an exercise price of $527.07 per share.
Rhea-AI Filing Summary
United Therapeutics Corp director Louis W. Sullivan received an annual non-employee director stock option award covering 2,380 shares of common stock at an exercise price of $527.07 per share. The options vest on the earlier of the one-year anniversary of the grant or the next Annual Meeting of Shareholders, anticipated on June 25, 2027, and expire on July 22, 2033. After this filing, he holds 2,983 common shares directly and 1,457 shares indirectly through a trust over which he has sole investment and voting power; totals were updated to correct a prior underreporting of 590 trust shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 2,380 shares
Grant/Award
3 txns
Insider
SULLIVAN LOUIS W
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option F3, F4 | 2,380 | $0.00 | $0.00 |
| holding | Common Stock F1 | -- | -- | -- |
| holding | Common Stock F2 | -- | -- | -- |
Holdings After Transaction:
Stock Option — 2,380 contracts (Direct);
Common Stock — 2,983 shares (Direct);
Common Stock — 1,457 shares (Indirect, by Trust)
Footnotes (4)
- F1. Total has been updated to correct a clerical error which caused the reporting person's indirect holding of common stock (by trust) to be underreported by 590 shares in the Form 4 filed on July 13, 2026 by the reporting person. These shares are in addition to the 2,903 shares held directly, as reported in the Form 4 filed on July 13, 2026.
- F2. These securities are held indirectly by a trust over which the reporting person has sole investment power and sole voting power.
- F3. Annual non-employee director award.
- F4. Annual non-employee director awards become fully vested on the earlier to occur of (a) the one-year anniversary of the grant date; or (b) the date of the next Annual Meeting of Shareholders following the grant date. June 25, 2027 is the anticipated date of the next Annual Meeting of Shareholders.
Key Figures
Options Granted: 2,380 options
Exercise Price: $527.07 per share
Option Expiration: July 22, 2033
+4 more
7 metrics
Options Granted
2,380 options
Annual non-employee director stock option award to Louis W. Sullivan
Exercise Price
$527.07 per share
Conversion or exercise price of the granted stock options
Option Expiration
July 22, 2033
Expiration date of the stock options granted
Expected Vesting Date
June 25, 2027
Anticipated date of the next Annual Meeting, when awards may fully vest
Direct Common Shares
2,983 shares
Total UTHR common stock held directly after reported transactions
Indirect Trust Shares
1,457 shares
Common stock held indirectly by a trust with sole voting and investment power
Clerical Error Adjustment
590 shares
Previously underreported indirect trust holdings corrected in this filing
Key Terms
Stock Option, Annual non-employee director award, Annual Meeting of Shareholders, indirect holding, +1 more
5 terms
Stock Option financial
"security_title: Stock Option; underlying security is Common Stock"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
Annual non-employee director award financial
"Footnote F3: Annual non-employee director award."
indirect holding financial
"caused the reporting person's indirect holding of common stock (by trust) to be underreported"
voting power financial
"held indirectly by a trust over which the reporting person has sole investment power and sole voting power"
Voting power is the ability shareholders have to influence a company's major decisions—like electing the board, approving mergers, or changing corporate rules—based on the voting rights attached to the shares they hold. For investors it matters because greater voting power is like holding more keys to a building: it gives you a stronger say over management choices and the company’s strategy, which can affect future value and risk.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did United Therapeutics (UTHR) report for Louis W. Sullivan?
Louis W. Sullivan received an annual non-employee director stock option award for 2,380 shares at an exercise price of $527.07 per share. The award is compensation-related, not an open-market purchase or sale, and vests based on director service and the next shareholder meeting.
What are the key terms of the new stock options granted at UTHR?
The grant consists of 2,380 stock options with an exercise price of $527.07 per share, expiring on July 22, 2033. The options vest on the earlier of the one-year anniversary of the grant or the next Annual Meeting of Shareholders, expected by June 25, 2027.
Did the UTHR filing correct any prior reporting errors for Louis W. Sullivan?
Yes. A footnote states that Sullivan’s indirect holdings by trust were previously underreported by 590 shares due to a clerical error. The totals disclosed in this filing have been updated to reflect the additional trust-held shares.
Are Louis W. Sullivan’s new UTHR options tied to a trading plan under Rule 10b5-1?
The filing’s Rule 10b5-1 checkbox is not marked as affirmed, and the footnotes describe the grant as an annual non-employee director award. The transactions reflect compensation awards rather than sales or purchases under a pre-arranged trading plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
